Your daily dose of the most actionable uptrends and downtrends on the ASX based on expert technical analysis.

CSL Limited, usually the bluest of blue-chip stocks on the ASX, has incinerated nearly $56 billion of its sharemarket value in the last 12 months. Now, the plasma and vaccines giant’s chair Brian ...

CSL Ltd (ASX: CSL) shares have not felt like a classic blue-chip winner lately. The biotechnology giant has disappointed the market, reset expectations, and left many long-term shareholders wondering ...

CSL is a global leader in plasma therapies, influenza vaccinations, and iron and kidney products. Shares have plummeted over 60% in the last two years on several earnings downgrades, significant ...

Amid the drama at the biotech, a new figure has stepped up right as the company needs a new long-term chief executive and chairman. Brian McNamee is CSL’s immovable object and unstoppable force. But ...

CSL shares have been hammered by earnings disappointments. But the long-term investment case remains strong. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium ...

CSL does not fit neatly into the typical biotech strategy mold. While much of the industry’s attention is focused on artificial intelligence (AI) drug discovery, obesity medicines, antibody-drug ...

This article first appeared on GuruFocus. CSL Ltd. (CMXHF) suffered its sharpest share-price drop on record after the Australian biotechnology company cut its full-year outlook, warned that its ...

In a 90-day review, CSL told the market it would take another $US5bn ($A6.9bn) non-cash impairment. The first $1.5bn of this was recognised during the first-half ...

CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the Australian company’s financial distress since its ill-fated 2022 ...

Shares in health giant CSL tanked today, with the stock closing 16 per cent lower, at $100.75. At earlier points in the session, the stock was down more than 20 per ...